![]() | |
Names | |
---|---|
Preferred IUPAC name
(2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | |
Other names
Ro-0728804, R-1439 | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.220.523 ![]() |
KEGG |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C24H23NO5S | |
Molar mass | 437.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
| |
---|---|
PPARαTooltip Peroxisome proliferator-activated receptor alpha |
|
PPARδTooltip Peroxisome proliferator-activated receptor delta |
|
PPARγTooltip Peroxisome proliferator-activated receptor gamma |
|
Non-selective |
|
|
![]() | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |